ReviewCurrent neuropharmacology2020
Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.
Review in Current neuropharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pooled it
- Cerebellar repetitive transcranial magnetic stimulation versus propranolol for essential tremor.Brain and behavior · 2023Trial
- Clinical Scales and Wearable Sensors in Patients with Essential Tremor Treated with Deep Brain Stimulation.Movement disorders clinical practice · 2026Article
- Effects of subanesthetic dose of ketamine on motor and cognitive outcomes of harmaline-induced essential tremor model: a focus on Lingo-1 and inflammatory pathways.BMC neuroscience · 2025Article
- Neuropsychiatric Approaches to Essential and Functional Tremor: A Comparative Study.Neuropsychiatric disease and treatment · 2025Article
- The impact of pregabalin and gabapentin on essential tremor: a systematic review and meta-analysis.Clinical parkinsonism & related disorders · 2025Review
- Ethics of deep brain stimulation for neuropsychiatric disorders.Neurosurgical review · 2024Review
- Review
- Patient-reported treatment satisfaction in essential tremor: levels of satisfaction and predictors of satisfaction.Therapeutic advances in neurological disorders · 2024Article
- Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy.CNS drugs · 2023Article
- Non-Persistence of Tremorolytic Effect of Perampanel in Essential Tremor: Real-World Experience with 50 Patients.Movement disorders clinical practice · 2023Article
- The Hidden Burden of Disease and Treatment Experiences of Patients with Essential Tremor: A Retrospective Claims Data Analysis.Advances in therapy · 2022Observational
- Diagnosis and Treatment of Essential Tremor.Continuum (Minneapolis, Minn.) · 2022Review
- Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- The Pathophysiology and Treatment of Essential Tremor: The Role of Adenosine and Dopamine Receptors in Animal Models.Biomolecules · 2021Review
- Genomic Markers for Essential Tremor.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Sleep Disorders in Patients with Essential Tremor.Current neurology and neuroscience reports · 2021Review
- Local Vibrational Therapy for Essential Tremor Reduction: A Clinical Study.Medicina (Kaunas, Lithuania) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEssential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data.
methodsA literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019.
resultsTo date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful.
conclusionInjections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABAA receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.